



MEDICAL PHARMACY – HEMOPHILIA

PRIOR AUTHORIZATION & DISPENSING

Prior Authorizations for Hemophilia Drugs

Bright HealthCare is requesting that providers submit service requests for the following Hemophilia drugs.

Qualified “Factor” Drugs

Advate	Hemlibra	Obizur
Adynovate*	Hemofil M	Profilnine
Afstyla	Humate-P	Rebinyn*
Alphanate	Idelvion*	Recombinate
AlphaNine SD	Ixinity	Rixubis
Alprolix *	Koate-DVI	Sevenfact
BeneFIX	Kogenate FS	Tretten
Coagadex	Kovaltry	Vonvendi
Corifact	Mononine	Wilate
Eloctate*	Novoeight	Xyntha
Esperoct*	NovoSeven RT	
Feiba	Nuwiq	

**Step therapy requirements and additional clinical parameters may need to be met prior to obtaining these products.*

How to Submit

Providers can submit Hemophilia Drug Product Prior Authorizations to Bright HealthCare by following the below instructions.

- Go to BrightHealthCare.com/provider/utilization-management
- Click on the member’s state
 - Within each state, information is split up by Individual and Family Plans and Small Group **OR** Medicare Advantage
- Select the Authorization Fax Form or Medical Outpatient Form (if applicable to the state)
- For “Service Being Requested,” select either:
 - “Medical Pharmacy – Drug Administration” **OR**
 - If Medical Pharmacy is not an option, select “Other” and write in “Hemophilia”
- Complete the entirety of the fax form

Effective January 1, 2022

- After completing the fax form, return to the Utilization Management page and the member's state
- Select the Hemophilia-specific supplemental form and complete it in its entirety
- Fax the forms to the fax number listed on the Authorization Fax Form or Medical Outpatient Form

After approval: Dispensing of Hemophilia Drugs

Bright HealthCare is partnering with MagellanRx for clinical review of dispensing for hemophilia drugs.

1. Once the authorization is approved, the dispensing pharmacy/rendering provider will be notified by MagellanRx to complete the "Hemophilia Case Review" form prior to each dispensing event for a monthly supply.

The **MagellanRx Hemophilia Case Review Form** is located on Bright HealthCare's Utilization Management page under the member's state:
brighthouse.com/provider/utilization-management.

2. Provider submits the **Hemophilia Case Review form** request to MagellanRx via telephone (800-424-7892) or fax (888-656-0841).
3. MagellanRx confirms the **Hemophilia Case Review form** and will work with the provider to ensure appropriate inventory and assay management.
4. MagellanRx faxes the dispensing approval notice to the dispensing pharmacy (a copy of the approval letter and dose review form will be emailed to Bright HealthCare).
5. At least 1 week prior to the expected factor depletion, a MagellanRx pharmacist will proactively reach out to the dispensing pharmacy.